Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The zonulin receptor refers primarily to Proteinase-Activated Receptor 2 (PAR2), a G protein-coupled receptor, which mediates the effects of zonulin (pre-haptoglobin 2) on intestinal permeability. Zonulin binding to PAR2 leads to transactivation of the Epidermal Growth Factor Receptor (EGFR), initiating downstream signaling pathways that disrupt tight junctions between epithelial cells. This process regulates paracellular transport and plays a role in various autoimmune, inflammatory, and metabolic diseases.
Activation of PAR2 by zonulin leads to EGFR transactivation, triggering intracellular signaling cascades that cause cytoskeletal reorganization and disruption of tight junction proteins, increasing paracellular permeability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zonulin Receptor.